ClinicalTrials.gg
CompletedNCT04431453CARAVANUpdated Feb 6, 2024Results posted

Study of Remdesivir in Participants Below 18 Years Old With COVID-19

A Phase 2/3 interventional study of Remdesivir in COVID-19, sponsored by Gilead Sciences. Completed at 32 sites in 4 countries. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2024-02-06.

Sponsored by Gilead Sciences · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
59
Allocation
Non-randomized
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies testing remdesivir in COVID-19 — 6 open to participants now, 9 under way, 3 of them phase 3. remdesivir · COVID-19.

Enrollment
36th of 40
59 · median 283
Started
2020
with 26 others
Phase 2/3
5 of 40
none open now
Registered
12th of 40
by date
Lead sponsor
6 of 40
Gilead Sciences

Among the 40 studies testing remdesivir in COVID-19, this one is the 36th largest by enrollment, is one of 27 that started in 2020, is one of 5 in phase 2/3, and was the 12th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

6 of the 40 studies testing remdesivir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About remdesivir

remdesivir: first FDA approval 2020 (VEKLURY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: Up to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing remdesivir in COVID-19, or all of them as a file.
02

Study summary

The goals of this clinical study are to learn more about the study drug, remdesivir, and how safe it is in participants less than 18 years old with coronavirus disease 2019 (COVID-19).

Read the detailed description

Pediatric participants will be enrolled as follows:

Pediatric participants ≥ 28 days to \< 18 years old:

  • Cohort 1: ≥ 12 years to \< 18 years and weight ≥ 40 kg
  • Cohort 2: ≥ 28 days to \< 18 years and weight ≥ 20 kg to \< 40 kg
  • Cohort 3: ≥ 28 days to \< 18 years and weight ≥ 12 kg to \< 20 kg
  • Cohort 4: ≥ 28 days to \< 18 years and weight ≥ 3 kg to \< 12 kg
  • Cohort 8: \< 12 years and weight ≥ 40 kg

Term neonatal participants 0 days to \< 28 days old:

  • Cohort 5: ≥ 14 days to \< 28 days of age, gestational age > 37 weeks and weight at screening ≥ 2.5 kg
  • Cohort 6: 0 days to \< 14 days of age, gestational age > 37 weeks and birth weight ≥ 2.5 kg

Preterm neonates and infants 0 days to \< 56 days old:

  • Cohort 7: 0 days to \< 56 days of age, gestational age ≤ 37 weeks and birth weight ≥ 1.5 kg
03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Aged \< 18 years of age who meet one of the following weight criteria (where permitted according to local law and approved nationally and by relevant institutional review board (IRB) or independent ethics committee (IEC)).

    • a) Cohort 1: ≥ 12 years to \< 18 years of age and weight at screening ≥ 40 kg
    • b) Cohorts 2-4: ≥ 28 days to \< 18 years of age and weight at screening ≥ 3 kg and \< 40 kg
    • c) Cohort 5: ≥ 14 days to \< 28 days of age, gestational age > 37 weeks and weight at screening ≥ 2.5 kg
    • d) Cohort 6: 0 days to \< 14 days of age, gestational age > 37 weeks and birth weight of ≥ 2.5 kg
    • e) Cohort 7: 0 days to \< 56 days of age, gestational age ≤ 37 weeks and birth weight of ≥ 1.5 kg
    • f) Cohort 8: \< 12 years of age and weight at screening ≥ 40 kg
  • Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection confirmed by polymerase chain reaction (PCR).
  • Hospitalized and requiring medical care for coronavirus disease 2019 (COVID-19).

Key Exclusion Criteria:

  • Concurrent treatment with other agents with actual or possible direct antiviral activity against SARS-CoV-2 \< 24 hours prior to study drug dosing.
  • (ALT) or aspartate aminotransferase (AST) > 5 X (ULN).
  • Estimated (eGFR) \< 30 mL/min/1.73m\^2 using Schwartz formula for individuals ≥ 1 year of age.
  • Creatinine above protocol specified thresholds for \< 1 year of age.
  • Positive pregnancy test at Screening only for female of child bearing potential. Note: If female participants who become pregnant during the study or are discovered to be pregnant after receiving at least one dose may continue study drug, after discussion with the investigator.
  • On renal replacement therapies (intermittent hemodialysis (iHD), peritoneal dialysis (PD), continuous renal replacement therapy (CRRT)).

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg

    Participants will receive RDV 200 mg, intravenous (IV) infusion on Day 1 followed by RDV 100 mg, IV infusion, daily, up to 10 days.

    Drug: Remdesivir

  • Experimental
    RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg

    Participants will receive RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion, daily, up to 10 days.

    Drug: Remdesivir

  • Experimental
    RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg

    Participants will receive RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion, daily, up to 10 days.

    Drug: Remdesivir

  • Experimental
    RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg

    Participants will receive RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion, daily, up to 10 days.

    Drug: Remdesivir

  • Experimental
    RDV, Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg

    Participants will receive RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion, daily, up to 10 days.

    Drug: Remdesivir

  • Experimental
    RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg

    Participants will receive RDV 2.5 mg/kg, IV infusion on Day 1 followed by RDV 1.25 mg/kg mg, IV, daily, up to 10 days.

    Drug: Remdesivir

  • Experimental
    RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg

    Participants will receive RDV 2.5 mg/kg, IV infusion on Day 1 followed by RDV 1.25 mg/kg mg, IV, daily, up to 10 days.

    Drug: Remdesivir

  • Experimental
    RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg

    Participants will receive RDV 200 mg, IV infusion on Day 1 followed by RDV 100 mg, IV infusion daily up to 10 days.

    Drug: Remdesivir

Interventions

  • Administered as an intravenous infusion

    Also known as: GS-5734™, Veklury®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

    TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug.

    Time frame: From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)

  2. Percentage of Participants With Treatment-Emergent Graded Laboratory Abnormalities

    Treatment-emergent graded laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any time post baseline up to and including the date of last dose of study drug plus 30 days. The laboratory abnormalities were graded using division of allergy and infectious diseases (DAIDS) scale. DAIDS scale is used to grade the severity of adult and pediatric unwanted medical events. Grade 1: mild event, Grade 2: moderate event, Grade: serious event, Grade 4: potentially life-threatening event.

    Time frame: From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)

  3. Pharmacokinetic (PK) Parameter: Cmax of Remdesivir and Its Metabolites GS-704277 and GS-441524 at Steady State

    Cmax is defined as maximum plasma concentration of drug. Plasma concentrations were drawn as follows: (1) for Cohorts 1-4 and 8 on Day 2 and Day 3 with Day 5 as optional; (2) for Cohorts 5-7 on Day 2 or Day 3.

    Time frame: Day 2: end of infusion and 4 hours post end of infusion, Day 3: pre-infusion and 2 hours post end of infusion, and Day 5: middle of infusion and 6 hours post end of infusion; infusion duration: 30 minutes to 2 hours

  4. PK Parameter: AUCtau of Remdesivir and Its Metabolites GS-704277 and GS-441524 at Steady State

    AUCtau is defined as area under the concentration versus time curve over the dosing interval. Plasma concentrations were drawn as follows: (1) for Cohorts 1-4 and 8 on Day 2 and Day 3 with Day 5 as optional; (2) for Cohorts 5-7 on Day 2 or Day 3.

    Time frame: Day 2: end of infusion and 4 hours post end of infusion, Day 3: pre-infusion and 2 hours post end of infusion, and Day 5: middle of infusion and 6 hours post end of infusion; infusion duration: 30 minutes to 2 hours

Secondary outcomes

  1. Percentage of Participants With Clinical Improvement on a 7-point Ordinal Scale Score

    Clinical improvement was defined as ≥ 1-point and ≥ 2-point improvement from Baseline clinical status or recovery or discharged alive on 7-point ordinal scale. Recovery was defined as an improvement from a Baseline score of 2 - 5 to a score of 6 or 7 or an improvement from a Baseline score of 6 to 7 on the ordinal scale. The ordinal scale was used for the assessment of the clinical status at a given day using a 7-point ordinal scale with an increasing score indicating improvement. Scale: 1=Death, 2=Hospitalized, on invasive mechanical ventilation or ECMO, 3=Hospitalized, on non-invasive ventilation or high flow oxygen devices, 4=Hospitalized, requiring low flow supplemental oxygen, 5=Hospitalized, not requiring supplemental oxygen-requiring ongoing medical care COVID-19 related or otherwise), 6=Hospitalized, not requiring supplemental oxygen-no longer required ongoing medical care (other than RDV administration), 7=Not hospitalized. The 95% CI was based on the Clopper-Pearson method.

    Time frame: Day 10

  2. Time (Days) to Discharge From Hospital

    Time to discharge was the duration from the first dose date to getting discharged from the hospital.

    Time frame: From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)

  3. Number of Participants With Change From Baseline in Oxygenation Use

    Oxygen support status was derived from the 7-point ordinal scale score, 1 = death; 2 = invasive mechanical ventilation; 3 = high flow oxygen; 4 = low flow oxygen; 5 or 6 = room air; 7 = discharge. Change from Baseline for participants with oxygenation use status as '3=High Flow Oxygen', '4=Low Flow Oxygen' and '5=Room Air' at Baseline.

    Time frame: Day 10

  4. Number of Participants With Change From Baseline in the Use of Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)

    Mechanical ventilation status was derived from the 7-point ordinal scale score, 1 = death; 2 = invasive mechanical ventilation; 3 = high flow oxygen; 4 = low flow oxygen; 5 or 6 = room air; 7 = discharge.

    Time frame: Day 10

  5. Days to First Confirmed Negative Polymerase Chain Reaction (PCR) Result

    Confirmed negative PCR is defined by as 2 consecutive negative PCR results or negative result at the last available sample for participants who completed or discontinued from the study. The assessment were done for the samples: nasal/oropharyngeal (OP), nasopharyngeal (NP)/oropharyngeal (OP), endotracheal (ET) aspirates, and rectal/fecal swabs.

    Time frame: From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)

  6. Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load Up to Day 10 or Up to the First Confirmed Negative PCR Result

    Change from baseline in SARS-CoV-2 viral load up to Day 10 or up to the first negative PCR result with confirmation (whichever comes first) were reported. The assessment were done for the samples: nasal/oropharyngeal (OP) samples, nasopharyngeal (NP)/OP samples, endotracheal (ET) aspirates, and rectal/fecal swabs.

    Time frame: Baseline, Day 10, and Day of Discharge (Day 10 or before)

  7. Bilirubin Concentrations in < 14-day-old Participants

    Time frame: From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)

  8. Percentage of Participants With Clinical Improvement Based on Scoring Using the Pediatric Early Warning Score (PEWS) Improvement Scale

    The PEWS was measured by 3 components, where 1= behavior, 2= perfusion assessed by capillary refill and heart rate, and 3= respiratory status assessed by respiratory rate, effort, and oxygen requirement. The score ranged between 0 to 9 point, with higher score representing the highest severity level. A negative change from baseline value indicated an improvement. Data are reported for participants with a PEWS behavior score ≥ 2 at baseline, and a ≥ 2-point improvement (indicated by a decrease) in PEWS behavior score by Day 10, participants with a PEWS behavior score ≥ 1 at baseline, with ≥ 1-point improvement in PEWS behavior score by Day 10 and participants who recovered in PEWS behavior, defined as a Baseline score of 1 through 3 improved to a score of 0.

    Time frame: Day 10

  9. Plasma Concentrations of Sulfobutylether β-cyclodextrin Sodium (SBECD)

    Plasma concentrations were drawn as follows: (1) for Cohorts 1-4 and 8 on Day 2 and Day 3, with Day 5 as optional; (2) for Cohorts 5-7 on Day 2 or Day 3.

    Time frame: Day 2: end of infusion and 4 hours post end of infusion, Day 3: pre-infusion and 2 hours post end of infusion, and Day 5: middle of infusion and 6 hours post end of infusion; infusion duration: 30 minutes to 2 hours

  10. Percentage of Participants With Concomitant Use of Medications Other Than RDV for Treatment of COVID-19

    Participants who received at least one concomitant non-study COVID-19 medication from the first day of RDV treatment through the 30-day Follow-up visit or early withdrawal are reported.

    Time frame: first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)

07

Results

Posted Dec 22, 2023

Participant flow

Participants were enrolled at study sites in Italy, Spain, the United Kingdom, and the United States.

Participant flow — Overall Study
MilestoneRemdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
Started121212124115
Completed11111193114
Not completed11131001
Withdrew: Withdrew consent01020000
Withdrew: Death10000001
Withdrew: Lost to follow-up00110000
Withdrew: Enrolled but never treated00001000

Outcome measures

PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug.

Time frame:
From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsRemdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)91.758.375.058.366.7——80.0
PrimaryPercentage of Participants With Treatment-Emergent Graded Laboratory Abnormalities

Treatment-emergent graded laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any time post baseline up to and including the date of last dose of study drug plus 30 days. The laboratory abnormalities were graded using division of allergy and infectious diseases (DAIDS) scale. DAIDS scale is used to grade the severity of adult and pediatric unwanted medical events. Grade 1: mild event, Grade 2: moderate event, Grade: serious event, Grade 4: potentially life-threatening event.

Time frame:
From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Graded Laboratory Abnormalities
percentage of participantsRemdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
Any grade10083.391.790.9100——80
Grade 3 or 47516.741.736.4100——60
PrimaryPharmacokinetic (PK) Parameter: Cmax of Remdesivir and Its Metabolites GS-704277 and GS-441524 at Steady State

Cmax is defined as maximum plasma concentration of drug. Plasma concentrations were drawn as follows: (1) for Cohorts 1-4 and 8 on Day 2 and Day 3 with Day 5 as optional; (2) for Cohorts 5-7 on Day 2 or Day 3.

Time frame:
Day 2: end of infusion and 4 hours post end of infusion, Day 3: pre-infusion and 2 hours post end of infusion, and Day 5: middle of infusion and 6 hours post end of infusion; infusion duration: 30 minutes to 2 hours
Reported as:
Mean · ng/mL
Pharmacokinetic (PK) Parameter: Cmax of Remdesivir and Its Metabolites GS-704277 and GS-441524 at Steady State
ng/mLRemdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
Remdesivir4108.7 ± 1365.156003.5 ± 1879.865980.1 ± 2284.085192.9 ± 2066.654829.0 ± 956.16——4235.7 ± 1790.53
GS-704277360.6 ± 208.11469.0 ± 239.72484.8 ± 244.07407.8 ± 132.45466.0 ± 110.87——297.9 ± 160.18
GS-441524276.4 ± 327.14210.5 ± 121.02186.5 ± 103.09209.8 ± 49.73371.8 ± 151.10——230.4 ± 255.03
PrimaryPK Parameter: AUCtau of Remdesivir and Its Metabolites GS-704277 and GS-441524 at Steady State

AUCtau is defined as area under the concentration versus time curve over the dosing interval. Plasma concentrations were drawn as follows: (1) for Cohorts 1-4 and 8 on Day 2 and Day 3 with Day 5 as optional; (2) for Cohorts 5-7 on Day 2 or Day 3.

Time frame:
Day 2: end of infusion and 4 hours post end of infusion, Day 3: pre-infusion and 2 hours post end of infusion, and Day 5: middle of infusion and 6 hours post end of infusion; infusion duration: 30 minutes to 2 hours
Reported as:
Mean · h*ng/mL
PK Parameter: AUCtau of Remdesivir and Its Metabolites GS-704277 and GS-441524 at Steady State
h*ng/mLRemdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
Remdesivir2630.1 ± 923.853937.9 ± 1981.406752.1 ± 10911.983625.7 ± 3361.192650.3 ± 587.77——2519.6 ± 1235.49
GS-7042771222.9 ± 1348.12860.3 ± 512.58876.0 ± 720.39776.0 ± 485.181049.0 ± 253.73——671.4 ± 553.30
GS-4415245486.2 ± 7599.273016.1 ± 2425.782751.8 ± 1868.932969.1 ± 940.736899.3 ± 3910.28——4336.8 ± 5692.30
SecondaryPercentage of Participants With Clinical Improvement on a 7-point Ordinal Scale Score

Clinical improvement was defined as ≥ 1-point and ≥ 2-point improvement from Baseline clinical status or recovery or discharged alive on 7-point ordinal scale. Recovery was defined as an improvement from a Baseline score of 2 - 5 to a score of 6 or 7 or an improvement from a Baseline score of 6 to 7 on the ordinal scale. The ordinal scale was used for the assessment of the clinical status at a given day using a 7-point ordinal scale with an increasing score indicating improvement. Scale: 1=Death, 2=Hospitalized, on invasive mechanical ventilation or ECMO, 3=Hospitalized, on non-invasive ventilation or high flow oxygen devices, 4=Hospitalized, requiring low flow supplemental oxygen, 5=Hospitalized, not requiring supplemental oxygen-requiring ongoing medical care COVID-19 related or otherwise), 6=Hospitalized, not requiring supplemental oxygen-no longer required ongoing medical care (other than RDV administration), 7=Not hospitalized. The 95% CI was based on the Clopper-Pearson method.

Time frame:
Day 10
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Improvement on a 7-point Ordinal Scale Score
percentage of participantsRemdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
≥ 1-point Improvement from Baseline50.0 (21.1 to 78.9)91.7 (61.5 to 99.8)100.0 (73.5 to 100.0)58.3 (27.7 to 84.8)33.3 (0.8 to 90.6)——80.0 (28.4 to 99.5)
≥ 2-point Improvement from Baseline41.7 (15.2 to 72.3)91.7 (61.5 to 99.8)100.0 (73.5 to 100.0)54.5 (23.4 to 83.3)33.3 (0.8 to 90.6)——80.0 (28.4 to 99.5)
Recovery25.0 (5.5 to 57.2)75.0 (42.8 to 94.5)91.7 (61.5 to 99.8)41.7 (15.2 to 72.3)33.3 (0.8 to 90.6)——80.0 (28.4 to 99.5)
SecondaryTime (Days) to Discharge From Hospital

Time to discharge was the duration from the first dose date to getting discharged from the hospital.

Time frame:
From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)
Reported as:
Median · days
Time (Days) to Discharge From Hospital
daysRemdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
Time (Days) to Discharge From Hospital12 (8 to 24)7 (5 to 9)5 (4 to 9)7 (4 to 19)NA (9 to NA)——10 (4 to 18)
SecondaryNumber of Participants With Change From Baseline in Oxygenation Use

Oxygen support status was derived from the 7-point ordinal scale score, 1 = death; 2 = invasive mechanical ventilation; 3 = high flow oxygen; 4 = low flow oxygen; 5 or 6 = room air; 7 = discharge. Change from Baseline for participants with oxygenation use status as '3=High Flow Oxygen', '4=Low Flow Oxygen' and '5=Room Air' at Baseline.

Time frame:
Day 10
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Oxygenation Use
ParticipantsRemdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
High flow oxygen (Baseline) — Death (Day 10)00000——0
High flow oxygen (Baseline) — IMV (Day 10)20000——1
High flow oxygen (Baseline) — High Flow oxygen (Day 10)10000——0
High flow oxygen (Baseline) — Low Flow oxygen (Day 10)00000——0
High flow oxygen (Baseline) — Room Air (Day 10)20000——0
High flow oxygen (Baseline) — Discharge (Day 10)14321——1
High flow oxygen (Baseline) — Missing (Day 10)00010——0
Low Flow Oxygen (Baseline) — Death (Day 10)00000——0
Low Flow Oxygen (Baseline) — IMV (Day 10)00000——0
Low Flow Oxygen (Baseline) — High Flow oxygen (Day 10)00000——0
Low Flow Oxygen (Baseline) — Low Flow oxygen (Day 10)00010——0
Low Flow Oxygen (Baseline) — Room Air (Day 10)10000——1
Low Flow Oxygen (Baseline) — Discharge (Day 10)13020——1
Low Flow Oxygen (Baseline) — Missing (Day 10)00000——0
Room Air (Baseline) — Death (Day 10)00000——0
Room Air (Baseline) — IMV (Day 10)00000——0
Room Air (Baseline) — High Flow oxygen (Day 10)00000——0
Room Air (Baseline) — Low Flow oxygen (Day 10)00000——0
Room Air (Baseline) — Room Air (Day 10)20000——0
Room Air (Baseline) — Discharge (Day 10)12610——1
Room Air (Baseline) — Missing (Day 10)00000——0
SecondaryNumber of Participants With Change From Baseline in the Use of Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)

Mechanical ventilation status was derived from the 7-point ordinal scale score, 1 = death; 2 = invasive mechanical ventilation; 3 = high flow oxygen; 4 = low flow oxygen; 5 or 6 = room air; 7 = discharge.

Time frame:
Day 10
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in the Use of Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)
ParticipantsRemdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
Death00000———
Invasive Mechanical ventilation11022———
High Flow Oxygen00000———
Low Flow Oxygen01000———
Room Air00120———
Discharge00200———
Missing01010———
SecondaryDays to First Confirmed Negative Polymerase Chain Reaction (PCR) Result

Confirmed negative PCR is defined by as 2 consecutive negative PCR results or negative result at the last available sample for participants who completed or discontinued from the study. The assessment were done for the samples: nasal/oropharyngeal (OP), nasopharyngeal (NP)/oropharyngeal (OP), endotracheal (ET) aspirates, and rectal/fecal swabs.

Time frame:
From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)
Reported as:
Median · days
Days to First Confirmed Negative Polymerase Chain Reaction (PCR) Result
daysRemdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
Nasal/OP SamplesNA (5 to NA)5 (3 to NA)7 (5 to NA)NA (4 to NA)10 (10 to 10)——NA (NA to NA)
NP/OP SamplesNA (NA to NA)NA (7 to NA)NA (5 to NA)NA (10 to NA)NA (NA to NA)——NA (NA to NA)
ET aspiratesNA (NA to NA)NA (3 to NA)NA (NA to NA)NA (3 to NA)NA (NA to NA)———
Rectal/Faecal samples5 (3 to 10)3 (3 to 5)5 (3 to NA)7 (5 to NA)3 (3 to 5)——4 (3 to 7)
SecondaryChange From Baseline in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load Up to Day 10 or Up to the First Confirmed Negative PCR Result

Change from baseline in SARS-CoV-2 viral load up to Day 10 or up to the first negative PCR result with confirmation (whichever comes first) were reported. The assessment were done for the samples: nasal/oropharyngeal (OP) samples, nasopharyngeal (NP)/OP samples, endotracheal (ET) aspirates, and rectal/fecal swabs.

Time frame:
Baseline, Day 10, and Day of Discharge (Day 10 or before)
Reported as:
Mean · log10 copies per mL
Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load Up to Day 10 or Up to the First Confirmed Negative PCR Result
log10 copies per mLRemdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
Nasal/OP Samples, Change at Day 10-3.01 ± NA—0 ± 0—-2.36 ± NA——-1.76 ± NA
Nasal/OP Samples, Change at Discharge—-4.65 ± NA—-1.56 ± 1.228————
NP/OP Samples, Change at Day 10—-2.17 ± 2.197—-2.60 ± 1.283-3.28 ± 0.183——0.46 ± NA
NP/OP Samples, Change at Discharge-2.86 ± NA-3.72 ± NA-0.87 ± 1.3911.42 ± NA———-0.05 ± 1.184
ET aspirates, Change at Day 10—-5.94 ± NA——-1.92 ± NA———
Rectal or Fecal Swabs, Change at Day 100.38 ± NA-0.39 ± NA—-1.87 ± NA———1.38 ± NA
Rectal or Fecal Swabs, Change at Discharge—1.12 ± NA-0.09 ± 1.999-1.47 ± 0.479———0 ± 0
SecondaryBilirubin Concentrations in < 14-day-old Participants
Time frame:
From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Clinical Improvement Based on Scoring Using the Pediatric Early Warning Score (PEWS) Improvement Scale

The PEWS was measured by 3 components, where 1= behavior, 2= perfusion assessed by capillary refill and heart rate, and 3= respiratory status assessed by respiratory rate, effort, and oxygen requirement. The score ranged between 0 to 9 point, with higher score representing the highest severity level. A negative change from baseline value indicated an improvement. Data are reported for participants with a PEWS behavior score ≥ 2 at baseline, and a ≥ 2-point improvement (indicated by a decrease) in PEWS behavior score by Day 10, participants with a PEWS behavior score ≥ 1 at baseline, with ≥ 1-point improvement in PEWS behavior score by Day 10 and participants who recovered in PEWS behavior, defined as a Baseline score of 1 through 3 improved to a score of 0.

Time frame:
Day 10
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Improvement Based on Scoring Using the Pediatric Early Warning Score (PEWS) Improvement Scale
percentage of participantsRemdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
≥ 2-point Improvement from Baseline- Respiratory33.3 (4.3 to 77.7)83.3 (35.9 to 99.6)75.0 (19.4 to 99.4)42.9 (9.9 to 81.6)0 (0 to 84.2)——66.7 (9.4 to 99.2)
≥ 1-point Improvement from Baseline- Respiratory50.0 (15.7 to 84.3)81.8 (48.2 to 97.7)83.3 (35.9 to 99.6)42.9 (9.9 to 81.6)33.3 (0.8 to 90.6)——66.7 (9.4 to 99.2)
Recovery- Respiratory37.5 (8.5 to 75.5)81.8 (48.2 to 97.7)83.3 (35.9 to 99.6)42.9 (9.9 to 81.6)33.3 (0.8 to 90.6)——66.7 (9.4 to 99.2)
≥ 2-point Improvement from Baseline- Behavior0 (0 to 84.2)33.3 (0.8 to 90.6)100 (47.8 to 100)66.7 (22.3 to 95.7)0 (0 to 84.2)——50 (1.3 to 98.7)
≥ 1-point Improvement from Baseline- Behavior40 (5.3 to 85.3)66.7 (22.3 to 95.7)100 (59 to 100)66.7 (29.9 to 92.5)66.7 (9.4 to 99.2)——33.3 (0.8 to 90.6)
Recovery- Behavior40 (5.3 to 85.3)66.7 (22.3 to 95.7)100 (59 to 100)55.6 (21.2 to 86.3)33.3 (0.8 to 90.6)——33 (0.8 to 90.6)
≥ 2-point Improvement from Baseline- Cardiovascular0 (0 to 84.2)66.7 (9.4 to 99.2)100 (15.8 to 100)100 (15.8 to 100)————
≥ 1-point Improvement from Baseline- Cardiovascular33.3 (0.8 to 90.6)80 (28.4 to 99.5)100 (47.8 to 100)66.7 (9.4 to 99.2)50 (1.3 to 98.7)——66.7 (9.4 to 99.2)
Recovery- Cardiovascular0 (0 to 70.8)80 (28.4 to 99.5)100 (47.8 to 100)33.3 (0.8 to 90.6)50 (1.3 to 98.7)——66.7 (9.4 to 99.2)
SecondaryPlasma Concentrations of Sulfobutylether β-cyclodextrin Sodium (SBECD)

Plasma concentrations were drawn as follows: (1) for Cohorts 1-4 and 8 on Day 2 and Day 3, with Day 5 as optional; (2) for Cohorts 5-7 on Day 2 or Day 3.

Time frame:
Day 2: end of infusion and 4 hours post end of infusion, Day 3: pre-infusion and 2 hours post end of infusion, and Day 5: middle of infusion and 6 hours post end of infusion; infusion duration: 30 minutes to 2 hours
Reported as:
Mean · ug/mL
Plasma Concentrations of Sulfobutylether β-cyclodextrin Sodium (SBECD)
ug/mLRemdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
Day 2, End of Infusion217.7 ± 262.32173.0 ± 119.06187.8 ± 75.89138.3 ± 104.06NA ± NA——156.6 ± 57.21
Day 2, 4 hours post infusion110.1 ± 270.7224.3 ± 23.9014.2 ± 15.0336.2 ± 32.75NA ± NA——16.2 ± 8.31
Day 3, Pre-Infusion78.5 ± 209.65NA ± NANA ± NANA ± NANA ± NA——NA ± NA
Day 3, 2 hours post infusion90.1 ± 221.5447.5 ± 52.6247.4 ± 38.9958.2 ± 25.8961.0 ± 79.20——48.0 ± 50.41
Day 5, Middle of Infusion229.0 ± 221.14105.5 ± 72.05156.3 ± 23.12118.2 ± 121.22———184.2 ± 131.82
Day 5, 6 Hours post infusion141.2 ± 261.966.6 ± 3.15NA ± NA12.4 ± 9.89———NA ± NA
SecondaryPercentage of Participants With Concomitant Use of Medications Other Than RDV for Treatment of COVID-19

Participants who received at least one concomitant non-study COVID-19 medication from the first day of RDV treatment through the 30-day Follow-up visit or early withdrawal are reported.

Time frame:
first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Concomitant Use of Medications Other Than RDV for Treatment of COVID-19
percentage of participantsRemdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
Percentage of Participants With Concomitant Use of Medications Other Than RDV for Treatment of COVID-19100.0100.083.383.366.7——100.0

Adverse events

Collected over All-Cause Mortality: First dose date up to approximately 8 weeks Adverse events: From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg2/12 (16.7%)5/12 (41.7%)11/12 (91.7%)
RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg1/12 (8.3%)2/12 (16.7%)7/12 (58.3%)
RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg0/12 (0%)0/12 (0%)9/12 (75%)
RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg.0/12 (0%)3/12 (25%)7/12 (58.3%)
RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg0/4 (0%)1/3 (33.3%)2/3 (66.7%)
RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg———
RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg———
RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg1/5 (20%)1/5 (20%)4/5 (80%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventRemdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg.RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
Cardiopulmonary failureCardiac disorders0/120/120/120/121/3——0/5
AcidosisMetabolism and nutrition disorders0/120/120/120/121/3——0/5
SeizureNervous system disorders0/120/120/120/121/3——0/5
PneumothoraxRespiratory, thoracic and mediastinal disorders0/120/120/120/121/3——0/5
Cardiac failureCardiac disorders0/120/120/120/120/3——1/5
Gastrointestinal necrosisGastrointestinal disorders0/120/120/120/120/3——1/5
PneumoperitoneumGastrointestinal disorders0/120/120/120/120/3——1/5
Multiple organ dysfunction syndromeGeneral disorders1/120/120/120/120/3——1/5
Respiratory distressRespiratory, thoracic and mediastinal disorders1/120/120/120/120/3——1/5
Haemodynamic instabilityVascular disorders0/120/120/120/120/3——1/5
Most frequent other events
Showing 10 of 113
Most frequent other events
EventRemdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg.RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kg
ConstipationGastrointestinal disorders3/121/122/121/120/3——3/5
HypomagnesaemiaMetabolism and nutrition disorders0/121/120/121/120/3——2/5
AnaemiaBlood and lymphatic system disorders1/121/120/121/121/3——0/5
Infusion site extravasationGeneral disorders0/122/120/120/121/3——0/5
Bacterial disease carrierInfections and infestations0/120/120/120/121/3——0/5
ConjunctivitisInfections and infestations0/120/120/120/121/3——0/5
Chest wall haematomaMusculoskeletal and connective tissue disorders0/120/120/120/121/3——0/5
Acute kidney injuryRenal and urinary disorders4/120/120/121/120/3——1/5
HypertensionVascular disorders2/121/120/120/121/3——1/5
Abdominal painGastrointestinal disorders1/120/120/120/120/3——1/5

Baseline characteristics

The Safety Analysis Set included all participants who were enrolled into the study and received at least 1 dose of study drug.

Age, Customized
Age, Customized(Participants)Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kgTotal
Newborns (0-27 days)00003——03
Infants and toddlers (28 days-23 months)001120——013
Children (2-11 years)081100——524
Adolescents (12-17 years)124000——016
Sex: Female, Male
Sex: Female, Male(Participants)Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kgTotal
Female87571——331
Male45752——225
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kgTotal
Hispanic or Latino37730——323
Not Hispanic or Latino85593——232
Unknown or Not Reported10000——01
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kgTotal
American Indian or Alaska Native00000——00
Asian00000——00
Native Hawaiian or Other Pacific Islander00000——00
Black or African American52420——114
White79683——336
More than one race01220——16
Unknown or Not Reported00000——00
Region of Enrollment
Region of Enrollment(participants)Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kgTotal
United States911992——343
United Kingdom00010——01
Italy00011——13
Spain31310——19
Number of Participants With Clinical Status (7-Point Ordinal Scale) Score
Number of Participants With Clinical Status (7-Point Ordinal Scale) Score(Participants)Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kgTotal
Score 100000——00
Score 213352——014
Score 364331——219
Score 423030——210
Score 532600——112
Score 600010——01
Score 700000——00
Oxygen Support Status
Oxygen Support Status(Participants)Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kgTotal
High Flow Oxygen64331——219
Low Flow Oxygen23030——210
Room Air32610——113
Invasive Mechanical Ventilation Status13352——014
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Ribonucleic Acid (RNA) Viral Load
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Ribonucleic Acid (RNA) Viral Load(log10 copies per mL)Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kgRDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kgRDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kgRDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kgRDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kgRDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kgRDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kgRDV, Cohort 8: < 12 Years and Weight ≥ 40 kgTotal
Nasal/oropharyngeal Swabs5.35 ± 1.7964.87 ± 2.8073.18 ± 0.9675.41 ± 2.1655.02 ± NA——6.20 ± NA4.80 ± 1.998
Nasopharyngeal/oropharyngeal Swabs5.93 ± 2.1725.37 ± 1.8795.67 ± 2.2735.55 ± 1.8545.99 ± 0.183——6.12 ± 1.6285.78 ± 1.802
Endotracheal Tube Aspirates5.36 ± NA5.58 ± 3.5546.09 ± 0.8406.68 ± 1.5404.63 ± NA———5.87 ± 2.180
Rectal/fecal Swabs3.30 ± 1.5932.63 ± 0.7572.72 ± 1.0343.84 ± 1.3414.27 ± 1.107——2.75 ± 1.2743.26 ± 1.297

1 further baseline measures are reported on the registry.

08

Study locations

32 sites
  • Children's Hospital of Alabama
    Birmingham, Alabama 35233, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Ronald Reagan University of California, Los Angeles Medical Center
    Los Angeles, California 90095, United States
  • Valley Children's Hospital
    Madera, California 93636, United States
  • UC Davis Medical center
    Sacramento, California 95817, United States
  • Rady Children's Hospital San Diego
    San Diego, California 92123, United States
  • Tampa General Hospital (Inpatient Visits)
    Tampa, Florida 33606, United States
  • Ann & Robert H. Lurie Children's Hospital
    Chicago, Illinois 60611, United States
  • Norton Children's Hospital
    Louisville, Kentucky 40202, United States
  • Tulane University School of Medicine
    New Orleans, Louisiana 70112, United States
  • Johns Hopkins Children's Center
    Baltimore, Maryland 21287, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Spectrum Health/Helen De Vos Children's Hospital
    Grand Rapids, Michigan 49503, United States
  • Children's Minnesota
    Minneapolis, Minnesota 55404, United States
  • NYC Health + Hospitals/Jacobi Medical Center
    Bronx, New York 10461, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Northwell Health-Cohen Children's Medical Center
    New Hyde Park, New York 11040, United States
  • Carolinas Medical Center-Levine Children's Hospital
    Charlotte, North Carolina 28203, United States
  • Lehigh Valley Hospital/Lehigh Valley Health Network (LVH/LVHN)
    Allentown, Pennsylvania 18103, United States
  • St. Christopher's Hospital for Children
    Philadelphia, Pennsylvania 19134, United States
  • Children's Medical Center
    Dallas, Texas 75235, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Azienda Ospedaliero Universitaria Meyer
    Florence, 50139, Italy
  • Azienda Ospedaliera di Padova - Dipartimento Salute della Donna e del Bambino
    Padova, 35128, Italy
  • UO Clinica Pediatrica, Ospedale Pietro Barilla - AOU di Parma
    Parma, 43126, Italy
  • Hospital Universitari Vall D'Hebron
    Barcelona, 8035, Spain
  • Hospital Sant Joan de Déu
    Esplugues de llobregat, 8950, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28009, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario La Paz
    Madrid, 28041, Spain
  • Hospital Clínico Universitario de Santiago
    Santiago de Compostela, 15706, Spain
  • Alder Hey Children's NHS Foundation Trust
    Liverpool, L12 2AP, United Kingdom
09

References and documents

Publications

  • Ahmed A, Rojo P, Agwu A, Kimberlin D, Deville J, Mendez-Echevarria A, et al. Remdesivir Treatment for COVID-19 in Hospitalized Children: CARAVAN Interim Results [Presentation]. European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2022; 2022 23-26 April; Lisbon, Portugal and Online.
  • Ahmed A, Rojo P, Agwu A, Kimberlin D, Deville J, Mendez-Echevarria A, et al. Remdesivir Treatment for COVID-19 in Hospitalized Children: CARAVAN Interim Results [Presentation]. Virtual Conference on Retroviruses and Opportunistic Infections (CROI) 2022; 2022c 12-16 February.
  • Munoz F, Muller W, Ahmed A, Kimberlin D, Mendez-Echevarria A, Chen JS, et al. Safety and efficacy of Remdesivir in a pediatric COVID-19 population (CROI) [Abstract 617]. Topics in antiviral medicine 2021;29 (1):237.
  • Pikora C, Bamford A, Luzuriaga K, Wiznia A, Rojo Conejo P, Muller B, et al. Challenges of remdesivir pediatric development for SARS-CoV-2 infection in a pandemic. 12th International Workshop on HIV Pediatrics; 2020 November 16-17; Virtual Event.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gileadclinicaltrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Feb 2023, 30 months.

Results were first posted in Dec 2023, 10 months after primary completion.

Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 30 months is above that.

Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2020
First posted
Jun 16, 2020
StartActual
Jul 21, 2020
Primary completionActual
Feb 10, 2023
CompletionActual
Feb 10, 2023
Results first posted
Dec 22, 2023
Last update
Feb 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04431453
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jun 16, 2020
Start date
Jul 21, 2020
Primary completion
Feb 10, 2023
Completion
Feb 10, 2023
Results posted
Dec 22, 2023
Last update
Feb 6, 2024

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remdesivir

Start the discussion